Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.64 |
| ▸ | RAF1 | P04049 | 15/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.62 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501502 | 0.93 | MAPK14 (0.65) | BRAFRAF1MAPK14HSPB1 | |
| SCHEMBL27727290 | 0.89 | MAPK14 (0.51) | BRAFRAF1MAPK14MAPK13HSPB1 | |
| SCHEMBL4501842 | 0.83 | MAPK14 (0.57) | BRAFRAF1MAPK14 | |
| SCHEMBL4506282 | 0.82 | MAPK14 (0.64) | BRAFRAF1MAPK14 | |
| SCHEMBL3048789 | 0.81 | MAPK14 (0.55) | RAF1MAPK14HSPB1 | |
| SCHEMBL12764085 | 0.79 | MAPK14 (0.69) | BRAFRAF1MAPK14MAPK13HSPB1 | |
| SCHEMBL4509580 | 0.78 | MAPK14 (0.55) | BRAFRAF1MAPK14HSPB1 | |
| SCHEMBL16034999 | 0.78 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL16034935 | 0.78 | BRAF (1.00) | BRAFRAF1MAPK14MAPK13HSPB1 | |
| SCHEMBL16121526 | 0.77 | RAF1 (1.00) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | claimed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | claimed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | claimed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | BRAF 64/4885RAF1 71/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.